Gastroesophageal reflux diseaseĝ€"from reflux episodes to mucosal inflammation

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 1, 2012, Pages 15-22

  Kandulski, Arne ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADX 10059; ANALGESIC AGENT; ARBACLOFEN PLACARBIL; AZD 1386; BACLOFEN; CANNABINOID 1 RECEPTOR; DIGESTIVE TRACT AGENT; DRONABINOL; INTERLEUKIN 1BETA; INTERLEUKIN 8; LESOGABERAN; MOSAPRIDE; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 2; PROTON PUMP INHIBITOR; RIMONABANT; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; BIOLOGICAL MARKER;

CELL HYPERPLASIA; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CYTOKINE RELEASE; DISEASE ACTIVITY; DRUG EFFECT; DRUG SAFETY; ESOPHAGEAL PH MONITORING; ESOPHAGITIS; ESOPHAGUS MUCOSA; ESOPHAGUS PAIN; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTOPATHOLOGY; HUMAN; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; LIVER FAILURE; LYMPHOCYTIC INFILTRATION; NERVOUS SYSTEM INFLAMMATION; NEUTROPHIL CHEMOTAXIS; NON EROSIVE REFLUX DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PH MEASUREMENT; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID; TH2 CELL; ANIMAL; GASTRITIS; IMMUNOLOGY; METABOLISM; MUCOSA; PATHOLOGY;

ANIMALS; BIOLOGICAL MARKERS; ESOPHAGITIS; GASTRITIS; GASTROESOPHAGEAL REFLUX; HUMANS; MUCOUS MEMBRANE;

EID: 84655163384     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.210     Document Type: Review

References (122)

1. Badreddine, R. J. & Wang, K. K. Barrett esophagus: an update. Nat Rev. Gastroenterol. Hepatol. 7, 369-378 (2010).
2. Odze, R. D. Barrett esophagus: histology and pathology for the clinician. Nat Rev. Gastroenterol. Hepatol. 6, 478-490 (2009).
3. Dent, J., el-Serag, H. B., Wallander, M. A. & Johansson, S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54, 710-717 (2005). (Pubitemid 40559260)
4. el-Serag, H. B. Time trends of gastroesophageal reflux disease: a systematic review. Clin. Gastroenterol. Hepatol. 5, 17-26 (2007). (Pubitemid 46096825)
5. Wiklund, I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig. Dis. 22, 108-114 (2004). (Pubitemid 39274305)
6. Kulig, M. et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease- an analysis based on the ProGERD initiative. Aliment Pharmacol. Ther. 18, 767-776 (2003). (Pubitemid 37323641)
7. Koelz, H. R., Blum, A. L. & Modlin, I. M. Costs of gerd: facts and fiction. Gastroenterology 125, 981-982 (2003).
8. Dent, J. et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 59, 714-721 (2010).
9. Savarino, V., Savarino, E., Parodi, A. & Dulbecco, P. Functional heartburn and non-erosive reflux disease. Dig. Dis. 25, 172-174 (2007). (Pubitemid 350194162)
10. rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112, 1448-1456 (1997). (Pubitemid 27181367)
11. Neumann, H., Monkemuller, K., Kandulski, A. & Malfertheiner, P. Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett's esophagus. Dig. Dis. 26, 243-247 (2008). (Pubitemid 351667808)
12. Galmiche, J. P. et al. Functional esophageal disorders. Gastroenterology 130, 1459-1465 (2006).
13. Vela, M. F., Craft, B. M., Sharma, N., Freeman, J. & Hazen-Martin, D. Refractory heartburn: comparison of intercellular space diameter in documented GERD vs. functional heartburn. Am. J. Gastroenterol. 106, 844-850 (2011).
14. Ronkainen, J. et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand. J. Gastroenterol. 40, 275-285 (2005). (Pubitemid 40476458)
15. Sharma, P. et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 131, 1392-1399 (2006). (Pubitemid 44708937)
16. Jankowski, J. A., Provenzale, D. & Moayyedi, P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 122, 588-590 (2002). (Pubitemid 34117010)
17. Yousef, F et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am. J. Epidemiol. 168, 237-249 (2008). (Pubitemid 352019777)
18. Labenz, J. et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am. J. Gastroenterol. 101, 2457-2462 (2006). (Pubitemid 44665238)
19. Malfertheiner, P. et al. Evolution of gastroesophageal reflux disease (GERD) over 5 years under routine medical care\-the ProGERD study. Aliment Pharmacol. Ther. (in press).
20. Orenstein, S. R., Shalaby, T. M., Kelsey, S. F. & Frankel, E. Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am. J. Gastroenterol. 101, 628-640 (2006). (Pubitemid 43340942)
21. Sherman, P. M. et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am. J. Gastroenterol. 104, 1278-1295 (2009).
22. Vakil, N., van Zanten, S. V., Kahrilas, P., Dent, J. & Jones, R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 101, 1900-1920 (2006).
23. Sifrim, D. & Holloway, R. Transient lower esophageal sphincter relaxations: how many or how harmful- Am. J. Gastroenterol. 96, 2529-2532 (2001). (Pubitemid 32889181)
24. Jacobson, B. C., Somers, S. C., Fuchs, C. S., Kelly, C. P. & Camargo, C. A. Jr. Body-mass index and symptoms of gastroesophageal reflux in women. N. Engl. J. Med. 354, 2340-2348 (2006). (Pubitemid 43801279)
25. Hampel, H., Abraham, N. S. & el-Serag, H. B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann. Intern. Med. 143, 199-211 (2005). (Pubitemid 41076753)
26. Barlow, W. J. & Orlando, R. C. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 128, 771-778 (2005). (Pubitemid 40585379)
27. Modlin, I. M. et al. Diagnosis and management of non-erosive reflux disease - the Vevey NERD Consensus Group. Digestion 80, 74-88 (2009).
28. Kahrilas, P. J. & Smout, A. J. Esophageal disorders. Am. J. Gastroenterol. 105, 747-756 (2010).
29. Dean, B. B., Gano, A. D. Jr, Knight, K., Ofman, J. J. & Fass, R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin. Gastroenterol. Hepatol. 2, 656-664 (2004). (Pubitemid 39013424)
30. Fass, R. & Sifrim, D. Management of heartburn not responding to proton pump inhibitors. Gut 58, 295-309 (2009).
31. Smout, A. J. The patient with GORD and chronically recurrent problems. Best Pract. Res. Clin. Gastroenterol. 21, 365-378 (2007). (Pubitemid 46825474)
32. Smith, J. L., Opekun, A. R., Larkai, E. & Graham, D. Y. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 96, 683-689 (1989). (Pubitemid 19057588)
33. Martinez, S. D., Malagon, I. B., Garewal, H. S., Cui, H. & Fass, R. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol. Ther. 17, 537-545 (2003). (Pubitemid 36384812)
34. Sifrim, D., Castell, D., Dent, J. & Kahrilas, P. J. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 53, 1024-1031 (2004). (Pubitemid 38824163)
35. Agrawal, A. et al. Symptoms with acid and nonacid reflux may be produced by different mechanisms. Dis. Esophagus 22, 467-470 (2009).
36. Vela, M. F. et al. Simultaneous intraesophageal mpedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 120, 1599-1606 (2001). (Pubitemid 32523479)
37. Sifrim, D. et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 120, 1588-1598 (2001). (Pubitemid 32523478)
38. Bredenoord, A. J., Weusten, B. L., Curvers, W. L., Timmer, R. & Smout, A. J. Determinants of perception of heartburn and regurgitation. Gut 55, 313-318 (2006). (Pubitemid 43268266)
39. Mainie, I. et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 55, 1398-1402 (2006). (Pubitemid 44476780)
40. Sharma, N., Agrawal, A., Freeman, J., Vela, M. F. & Castell, D. An analysis of persistent symptoms in acid-suppressed patients undergoing mpedance-pH monitoring. Clin. Gastroenterol. Hepatol. 6, 521-524 (2008).
41. Hemmink, G. J. et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor- Am. J. Gastroenterol. 103, 2446-2453 (2008).
42. Furuta, T. et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by ansoprazole. Clin. Pharmacol. Ther. 72, 453-460 (2002). (Pubitemid 35178870)
43. Furuta, T. et al. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose ansoprazole. Eur. J. Clin. Pharmacol. 65, 693-698 (2009).
44. Fass, R., Shapiro, M., Dekel, R. & Sewell, J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease\-where next- Aliment Pharmacol. Ther. 22, 79-94 (2005). (Pubitemid 41039696)
45. Ismail-Beigi, F., Horton, P. F & Pope, C. E. Histological consequences of gastroesophageal reflux in man. Gastroenterology 58, 163-174 (1970).
46. Hopwood, D., Milne, G. & Logan, K. R. Electron microscopic changes in human oesophageal epithelium in oesophagitis. J. Pathol. 129, 161-167 (1979). (Pubitemid 10214410)
47. Tobey, N. A., Carson, J. L, Alkiek, R. A. & Orlando, R. C. Dilated intercellular spaces: a morphological feature of acid reflux\-damaged human esophageal epithelium. Gastroenterology 111, 1200-1205 (1996). (Pubitemid 26362244)
48. Tobey, N. A. et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am. J. Gastroenterol. 99, 13-22 (2004). (Pubitemid 38679095)
49. Vieth, M. et al. Radial distribution of dilated intercellular spaces of the esophageal squamous epithelium in patients with reflux disease exhibiting discrete endoscopic lesions. Dig. Dis. 22, 208-212 (2004). (Pubitemid 39274318)
50. Vieth, M. et al. What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett's mucosa- Dig. Dis. 22, 196-201 (2004). (Pubitemid 39274316)
51. Zentilin, P. et al. Carditis in patients with gastro-oesophageal reflux disease: results of a controlled study based on both endoscopy and 24-h oesophageal pH monitoring. Aliment. Pharmacol. Ther. 19, 1285-1292 (2004). (Pubitemid 38859505)
52. Fiocca, R. et al. Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: the Esohisto project. Hum. Pathol. 41, 223-231 (2010).
53. Yerian, L. et al. Refinement and reproducibility of histologic criteria for the assessment of microscopic lesions in patients with gastroesophageal reflux disease: the esohisto project. Dig. Dis. Sci. 56, 2656-2665 (2011).
54. Fiocca, R. et al. Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. Am. J. Gastroenterol. 105, 1015-1023 (2010).
55. Galmiche, J. P. et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 305, 1969-1977 (2011).
56. Farre, R. et al. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces. Gut 57, 1366-1374 (2008).
57. Tobey, N. A., Gambling, T M., Vanegas, X. C., Carson, J. L. & Orlando, R. C. Physicochemical basis for dilated intercellular spaces in non-erosive acid-damaged rabbit esophageal epithelium. Dis. Esophagus 21, 757-764 (2008).
58. Carney, C. N., Orlando, R. C., Powell, D. W. & Dotson, M. M. Morphologic alterations in early acid-induced epithelial injury of the rabbit esophagus. Lab. Invest. 45, 198-208 (1981). (Pubitemid 11012893)
59. Farre, R. et al. Acid and weakly acidic solutions mpair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut 59, 164-169 (2010).
60. Farre, R. et al. Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique. Gut 60, 885-892 (2011).
61. Haggitt, R. C. Histopathology of reflux-induced esophageal and supraesophageal injuries. Am. J. Med. 108 (Suppl. 4a), 109S-111S (2000).
62. Odze, R. D. Unraveling the mystery of the gastroesophageal junction: a pathologist's perspective. Am. J. Gastroenterol. 100, 1853-1867 (2005). (Pubitemid 41648443)
63. Tummala, V., Barwick, K. W., Sontag, S. J., Vlahcevic, R. Z. & McCallum, R. W. The significance of intraepithelial eosinophils in the histologic diagnosis of gastroesophageal reflux. Am. J. Clin. Pathol. 87, 43-48 (1987). (Pubitemid 17216823)
64. Livstone, E. M., Sheahan, D. G. & Behar, J. Studies of esophageal epithelial cell proliferation in patients with reflux esophagitis. Gastroenterology 73, 1315-1319 (1977). (Pubitemid 8229283)
65. Tobey, N. A. et al. The role of pepsin in acid injury to esophageal epithelium. Am. J. Gastroenterol. 96, 3062-3070 (2001). (Pubitemid 33095343)
66. Orlando, R. C. Pathophysiology of gastroesophageal reflux disease. J. Clin. Gastroenterol. 42, 584-588 (2008). (Pubitemid 351572264)
67. Fitzgerald, R. C. Inflammation at the neo squamocolumnar junction in Barrett's oesophagus. Gut 47, 870 (2000).
68. Fitzgerald, R. C. et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50, 451-459 (2002). (Pubitemid 34638860)
69. Kandulski, A. et al. Chronic mucosal inflammation of the gastric cardia in gastroesophageal reflux disease is not regulated by FOXP3-expressing T cells. Dig. Dis. Sci. 54, 1940-1946 (2009).
70. Isomoto, H. et al. Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis. Am. J. Gastroenterol. 98, 551-556 (2003). (Pubitemid 36348524)
71. Yoshida, N. et al. Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. Int. J. Mol. Med. 19, 335-340 (2007).
72. Monkemuller, K. et al. Interleukin-1ßand interleukin-8 expression correlate with the histomorphological changes in esophageal mucosa of patients with erosive and non-erosive reflux disease. Digestion 79, 186-195 (2009).
73. Yamaguchi, T. et al. Cytokine-induced neutrophil accumulation in the pathogenesis of acute reflux esophagitis in rats. Int. J. Mol. Med. 16, 71-77 (2005).
74. Rieder, F. et al. Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities. Gastroenterology 132, 154-165 (2007). (Pubitemid 46108733)
75. Cheng, L. et al. HCl-induced inflammatory mediators in cat esophageal mucosa and inflammatory mediators in esophageal circular muscle in an in vitro model of esophagitis. Am. J. Physiol. Gastrointest Liver Physiol. 290, G1307-G1317 (2006). (Pubitemid 43788314)
76. Isomoto, H. et al. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease. Am. J. Gastroenterol. 99, 589-597 (2004). (Pubitemid 38607958)
77. Oh, D. S. et al. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. Arch. Surg. 142, 554-559 (2007). (Pubitemid 46956405)
78. Mukaida, N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am. J. Physiol. Lung Cell. Mol. Physiol. 284, L566-L577 (2003). (Pubitemid 36343304)
79. Hamaguchi, M. et al. Increased expression of cytokines and adhesion molecules in rat chronic esophagitis. Digestion 68, 189-197 (2003). (Pubitemid 38250508)
80. Cheng, L. et al. Acid-induced release of platelet-activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle. J. Pharmacol. Exp. Ther. 319, 117-126 (2006). (Pubitemid 44455116)
81. Cheng, L. et al. In vitro model of acute esophagitis in the cat. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G860-G869 (2005). (Pubitemid 41532579)
82. Rieder, F., Biancani, P., Harnett, K., Yerian, L. & Falk, G. W. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am. J. Physiol. Gastrointest Liver Physiol. 298, G571-G581 (2010).
83. Kandulski, A. et al. Proteinase-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease. Am. J. Gastroenterol. 105, 1934-1943 (2010).
84. Souza, R. F. et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 137, 1776-1784 (2009).
85. Yoshida, N. et al. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand. J. Gastroenterol. 39, 816-822 (2004). (Pubitemid 39215451)
86. Steinhoff, M. et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 6, 151-158 (2000). (Pubitemid 30082358)
87. Soreide, K. Proteinase-activated receptor 2 (PAR-2) in gastrointestinal and pancreatic pathophysiology, inflammation and neoplasia. Scand. J. Gastroenterol. 43, 902-909 (2008).
88. Scarborough, R. M. et al. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J. Biol. Chem. 267, 13146-13149 (1992).
89. Dery, O., Corvera, C. U., Steinhoff, M. & Bunnett, N. W. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am. J. Physiol. 274, C1429-C1452 (1998).
90. Cenac, N. et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am. J. Pathol. 161, 1903-1915 (2002). (Pubitemid 35265547)
91. Vergnolle, N. et al. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med. 7, 821-826 (2001). (Pubitemid 32691637)
92. Coelho, A. M., Vergnolle, N., Guiard, B., Fioramonti, J. & Bueno, L. Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. Gastroenterology 122, 1035-1047 (2002). (Pubitemid 34267286)
93. Jacob, C. et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and ß-arrestins. J. Biol. Chem. 280, 31936-31948 (2005). (Pubitemid 41291944)
94. Soderholm, J. D. Stress-related changes in oesophageal permeability: filling the gaps of GORD- Gut 56, 1177-1180 (2007). (Pubitemid 47300411)
95. Souza, R. F. Bringing GERD management up to PAR-2. Am. J. Gastroenterol. 105, 1944-1946 (2010).
96. Naito, Y et al. Role of pancreatic trypsin in chronic esophagitis induced by gastroduodenal reflux in rats. J. Gastroenterol. 41, 198-208 (2006).
97. Amadesi, S. et al. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J. Neurosci. 24, 4300-4312 (2004). (Pubitemid 38608141)
98. Bhat, Y M. & Bielefeldt, K. Capsaicin receptor (TRPV1) and non-erosive reflux disease. Eur. J. Gastroenterol. Hepatol. 18, 263-270 (2006).
99. Matthews, P. J. et al. Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur. J. Gastroenterol. Hepatol. 16, 897-902 (2004).
100. Guarino, M. P. et al. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol. Motil. 22, 746-751, e219 (2010).
101. Cortright, D. N. & Szallasi, A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur. J. Biochem. 271, 1814-1819 (2004). (Pubitemid 38657335)
102. Kindt, S., Vos, R., Blondeau, K. & Tack, J. Influence of intra-oesophageal capsaicin instillation on heartburn induction and oesophageal sensitivity in man. Neurogastroenterol. Motil. 21, 1032-e82 (2009).
103. Yiangou, Y et al. Vanilloid receptor 1 mmunoreactivity in inflamed human bowel. Lancet 357, 1338-1339 (2001). (Pubitemid 32441536)
104. Cheng, L. et al. HCl-activated neural and epithelial vanilloid receptors (TRPV1) in cat esophageal mucosa. Am. J. Physiol. Gastrointest Liver Physiol. 297, G135-G143 (2009).
105. Ma, J., Harnett, K. M., Behar, J., Biancani, P. & Cao, W. Signaling in TRPV1-induced platelet activating factor (PAF) in human esophageal epithelial cells. Am. J. Physiol. Gastrointest Liver Physiol. 298, G233-G240 (2010).
106. Shieh, K. R. et al. Evidence for neurotrophic factors associating with TRPV1 gene expression in the inflamed human esophagus. Neurogastroenterol. Motil. 22, 971-7, e252 (2010).
107. B agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52, 1397-1402 (2003). (Pubitemid 37176716)
108. Vela, M. F., Tutuian, R., Katz, P. O. & Castell, D. O. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol. Ther. 17, 243-251 (2003). (Pubitemid 36174255)
109. Gerson, L. B. et al. Arbaclofen placarbi decreases postprandial reflux in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 105, 1266-1275 (2010).
110. Boeckxstaens, G. E. et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 139, 409-417 (2010).
111. Zerbib, F. et al. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment Pharmacol. Ther. 33, 911-921 (2011).
112. Zerbib, F., Keywood, C. & Strabach, G. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol. Motil. 22, 859-865, e231 (2010).
113. Keywood, C., Wakefield, M. & Tack, J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 58, 1192-1199 (2009).
114. Ruth, M., Hamelin, B., Rohss, K. & Lundell, L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol. Ther. 12, 35-40 (1998). (Pubitemid 28057402)
115. Ruth, M., Finizia, C., Cange, L. & Lundell, L. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 15, 1115-1121 (2003). (Pubitemid 37267228)
116. Cho, Y K. et al. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. J. Clin. Gastroenterol. 40, 286-292 (2006). (Pubitemid 44309518)
117. Lehmann, A. et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 123, 1129-1134 (2002).
118. Partosoedarso, E. R., Abrahams, T. P., Scullion, R. T., Moerschbaecher, J. M. & Hornby, P. J. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J. Physiol. 550, 149-158 (2003). (Pubitemid 36869276)
119. Beaumont, H. et al. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br. J. Pharmacol. 156, 153-162 (2009).
120. Scarpellini, E. et al. Effect of rimonabant on oesophageal motor function in man. Aliment Pharmacol. Ther. 33, 730-737 (2011).
121. Broekaert, D., Fischler, B., Sifrim, D., Janssens, J. & Tack, J. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol. Ther. 23, 365-370 (2006). (Pubitemid 43382016)
122. Krarup, A. L. et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol. Ther. 33, 1113-1122 (2011).